validation with a miniaturized Bluetooth-enabled printed circuit board (PCB) controller powered by a 3 V coin cell battery further supports the platform's feasibility for autonomous, wirelessly controlled therapeutic administration. Together, these findings demonstrate a scalable, low-power, and highly adaptable nanofluidic system capable of tunable drug delivery, suitable for integration within implantable closed-loop systems.